摘要
脑卒中具有高致死率、高致残率和高复发率的特点,对于急性脑梗死目前采用溶栓治疗、抗血小板治疗等措施。溶栓和非溶栓治疗的患者均存在出血转化(HT)的风险。本研究对哈尔滨市第四医院2020年1月至2021年10月2例非溶栓性脑梗死HT患者进行汇报及病例分析,2例患者采用降纤、抗血小板聚集、清除自由基治疗及巴曲酶降纤治疗。巴曲酶是由蛇毒中提取的单一成分的类凝血酶,目前,鲜见巴曲酶所致非溶栓性脑梗死HT病例报告。
Stroke is characterized by high fatality rate,high disability rate and high recurrence rate,and thrombolytic therapy and antiplatelet therapy are currently used for acute cerebral infarction.Both thrombolytic and non-thrombolytic treated patients may be at risk of hemorrhagic transformation(HT).This paper herein reports and studies 2 patients with HT after non-thrombolytic cerebral infarction who were treated with fibrinlowering,antiplatelet aggregation,free radical scavenging and fibrin-lowering with batroxobin in the Fourth Hospital of Harbin from January 2020 to October 2021.Batroxobin is a single-component thrombin-like enzyme derived from snake venom,and few cases of HT after non-thrombolytic cerebral infarction induced by this drug have been reported.
作者
王凝瑶
薛伟书
王楠
徐国慧
尚雪莹
WANG Ningyao;XUE Weishu;WANG Nan;XU Guohui;SHANG Xueying(Department of NeurologyⅡ,the Fourth Hospital of Harbin,Heilongjiang,Harbin 150026,China)
出处
《中国医药科学》
2022年第16期197-200,共4页
China Medicine And Pharmacy
基金
黑龙江省卫生健康委科研课题(2020-028)。
关键词
脑梗死
出血转化
溶栓
抗凝药
血小板聚集抑制剂
Cerebral infarction
Hemorrhagic transformation
Thrombolysis
Anticoagulant
Platelet aggregation inhibitor
